RAB3C

Across TCGA pan-cancer cohorts, RAB3C mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RAB3C data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RAB3C mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RAB3C expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where RAB3C mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.937	0.433	<.001	58	view →
HNSC	DFS	Median	II,III,IV	0.888	1.000	.021	6	view →
LUAD	OS	Median	All	0.433	1.000	.012	4	view →
CCRCC	DFS	Tertile	All	0.344	1.000	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RAB3C–PDAC (DFS)

Open the PDAC breakdown →